HLB Pharmaceutical Co

HLB Pharmaceutical Co Quick Ratio

The Quick Ratio (Acid Test) of HLB Pharmaceutical Co (047920.KQ) as of Nov 8, 2026 is 0.02. In the previous year, Quick Ratio (Acid Test) was 1.21 — a change of -98.05% (lower).

Quick Ratio

0.02

YoY

-98.05%

Last updated:

Quick Ratio (Acid Test) of HLB Pharmaceutical Co is 2025 0.02 . Quick Ratio (Acid Test) of HLB Pharmaceutical Co was 2024 1.21 . It decreases by -98.05% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HLB Pharmaceutical Co Stock analysis

What does HLB Pharmaceutical Co do? HLB Pharmaceutical Co., Ltd. generates revenue through the manufacturing and sale of biotechnology-based pharmaceutical products. The company produces and sells cimetidine tablets, rozatin tablets, rabeprazole tablets, rozatinplus tablets, mosapia tablets, and other ethical the counter (ETC) drugs, as well as gynobetadine vaginal suppositories and other over the counter (OTC) drugs. Additionally, HLB offers commissioned ETC drugs such as aceclofenac tablets and revotec tablets, and commissioned OTC drugs including L-carnitine tablets, elcatan tablets, and hepatine liquids. These products are sold to healthcare providers, pharmacies, and consumers through established distribution channels. The primary customer segments for HLB's products include healthcare institutions requiring ETC drugs for prescription use, retail pharmacies selling OTC medications, and individual consumers purchasing OTC products directly. The company's product portfolio targets both prescription and non-prescription markets, with ETC drugs typically distributed through medical channels and OTC drugs available through general retail outlets. HLB's focus on biotechnology-driven formulations positions it within the pharmaceutical sector serving diverse healthcare needs. HLB's revenue streams are derived from direct sales of its branded pharmaceutical products to healthcare providers and retail networks. The company's ETC drugs, such as cimetidine and rabeprazole tablets, are primarily sold to hospitals and clinics for prescription use, while OTC products like gynobetadine vaginal suppositories and L-carnitine tablets reach consumers through pharmacy chains and online platforms. Commissioned products further diversify revenue by leveraging partnerships for manufacturing and distribution without direct brand ownership. HLB Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HLB Pharmaceutical Co stock

Quick Ratio (Acid Test) of HLB Pharmaceutical Co is 0.02 in 2025.

Quick Ratio (Acid Test) of HLB Pharmaceutical Co changed from 1.21 to 0.02, representing a -98.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) HLB Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s HLB Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — HLB Pharmaceutical Co

All Key Metrics — HLB Pharmaceutical Co